Costimulatory Agonists Start to Bear Fruit in Oncology
Aaron R. Hansen, BSc, MBBS, discusses progress with costimulatory immune checkpoints in oncology.
CDK4/6 Inhibitors Explored in Adjuvant Breast Cancer Setting
Recently, CDK 4/6 inhibitors have been changing practice in advanced HR-positive breast cancer, with 3 agents now having FDA-approved indications for use with endocrine therapy in the first-line setting.
Checkpoint Inhibitors Herald New Era in Urothelial Cancer
Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.
Study Finds No Cognitive Effects From Endocrine Therapy
Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.
Closer Study Required of Immunological Differences Between Sexes
Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.
Finding a Place for Stimulatory Immune Checkpoint Antibodies
When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.
AI Will Converge With Physician-Directed Care
Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine.
Drugs Make Progress in Breaching the Blood-Brain Barrier
Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.
Looking for Zebras in Metastatic Colorectal Cancer
During a recent OncLive Peer Exchange®, a panel of CRC experts discussed the heterogeneity of metastatic CRC and the need to identify patient subsets within this disease to enable a precision medicine approach.
Added Factors Put the Overall Survival Endpoint to the Test
The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.